CA2343236A1 - Derives de 4,4-biarylpiperidine - Google Patents

Derives de 4,4-biarylpiperidine Download PDF

Info

Publication number
CA2343236A1
CA2343236A1 CA002343236A CA2343236A CA2343236A1 CA 2343236 A1 CA2343236 A1 CA 2343236A1 CA 002343236 A CA002343236 A CA 002343236A CA 2343236 A CA2343236 A CA 2343236A CA 2343236 A1 CA2343236 A1 CA 2343236A1
Authority
CA
Canada
Prior art keywords
compounds
biarylpiperidine
derivatives
biarylpiperidine derivatives
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002343236A
Other languages
English (en)
Other versions
CA2343236C (fr
Inventor
Spiros Liras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2343236A1 publication Critical patent/CA2343236A1/fr
Application granted granted Critical
Publication of CA2343236C publication Critical patent/CA2343236C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA002343236A 1998-09-09 1999-09-06 Derives de 4,4-biarylpiperidine Expired - Fee Related CA2343236C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9956598P 1998-09-09 1998-09-09
US60/099,565 1998-09-09
PCT/IB1999/001512 WO2000014066A1 (fr) 1998-09-09 1999-09-06 Derives de 4,4-biarylpiperidine possedant une activite de recepteur opioide

Publications (2)

Publication Number Publication Date
CA2343236A1 true CA2343236A1 (fr) 2000-03-16
CA2343236C CA2343236C (fr) 2006-01-03

Family

ID=22275622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002343236A Expired - Fee Related CA2343236C (fr) 1998-09-09 1999-09-06 Derives de 4,4-biarylpiperidine

Country Status (41)

Country Link
US (2) US6720336B2 (fr)
EP (1) EP1112255B1 (fr)
JP (1) JP2002524445A (fr)
KR (1) KR20010075024A (fr)
CN (1) CN1316993A (fr)
AP (1) AP2001002088A0 (fr)
AR (1) AR022376A1 (fr)
AT (1) ATE312819T1 (fr)
AU (1) AU749096B2 (fr)
BG (1) BG105411A (fr)
BR (1) BR9913512A (fr)
CA (1) CA2343236C (fr)
CO (1) CO5170416A1 (fr)
CZ (1) CZ2001850A3 (fr)
DE (1) DE69928945T2 (fr)
EA (1) EA200100203A1 (fr)
EE (1) EE200100145A (fr)
ES (1) ES2252960T3 (fr)
GE (1) GEP20033025B (fr)
GT (1) GT199900146A (fr)
HK (1) HK1040396A1 (fr)
HN (1) HN1999000149A (fr)
HR (1) HRP20010167A2 (fr)
HU (1) HUP0103542A3 (fr)
ID (1) ID29129A (fr)
IL (1) IL141506A0 (fr)
IS (1) IS5860A (fr)
MA (1) MA26686A1 (fr)
NO (1) NO20011183L (fr)
NZ (1) NZ509841A (fr)
OA (1) OA11648A (fr)
PA (1) PA8481301A1 (fr)
PE (1) PE20001053A1 (fr)
PL (1) PL346648A1 (fr)
SK (1) SK3032001A3 (fr)
SV (1) SV1999000147A (fr)
TN (1) TNSN99169A1 (fr)
TR (1) TR200100694T2 (fr)
WO (1) WO2000014066A1 (fr)
YU (1) YU11501A (fr)
ZA (1) ZA200101744B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1038872A1 (fr) * 1999-02-22 2000-09-27 Pfizer Products Inc. Dérivés de 4-phényl-4-hétéroarylpiperdine comme ligands des récepteurs opioides
SE9902765D0 (sv) * 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
US6974824B2 (en) * 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
EP1279666A1 (fr) * 2001-07-24 2003-01-29 Pfizer Products Inc. Dérivés de 1-diphenylméthyl-pyrazoles comme ligands des récepteurs opioides
US7045520B2 (en) 2002-02-07 2006-05-16 The Curators Of The University Of Missouri Opioid receptor active compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203301D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
ES2321509T3 (es) 2002-11-26 2009-06-08 Pfizer Products Inc. Compuestos de piperidina sustituidos con fenilo para usar como activadores de ppar.
ES2528631T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
AR044010A1 (es) * 2003-04-11 2005-08-24 Janssen Pharmaceutica Nv Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica
JPWO2005037269A1 (ja) * 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
WO2005061463A1 (fr) 2003-12-23 2005-07-07 Astex Therapeutics Limited Derives de pyrazole servant de modulateurs de proteine kinase
EP1584335A3 (fr) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Combinaison de substances actives comprenant un composé carbinol et un opioïde
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) * 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2006136823A1 (fr) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Amine contenant des heterocycliques comme inhibiteurs des kinases b
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
DE102005061427A1 (de) * 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxadiazol-Derivate
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EP2139890B1 (fr) 2007-03-29 2014-06-25 Wyeth LLC Récepteur antagonistes d'opioïde périphériques et utilisations de ceux-ci
WO2008121348A2 (fr) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Antagonistes de récepteurs opioïdes périphériques, et leurs utilisations
CA2682129A1 (fr) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Formes cristallines et leurs utilisations
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
EP2263664A1 (fr) * 2009-05-18 2010-12-22 Nestec S.A. Composé (thymoquinone, Nigella sativa) stimulant les récepteurs opioïdes et allergie alimentaire
SG11201906430RA (en) * 2017-01-17 2019-08-27 Mebias Discovery Inc Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
CA3055215A1 (fr) * 2017-03-12 2018-09-20 Xiaodong Wang Amines polycycliques utilisees comme modulateurs des recepteurs opioides
US11584765B2 (en) 2017-03-12 2023-02-21 Ecstasy LLC Polycyclic amines as sigma receptor modulators
US10258357B1 (en) * 2017-10-16 2019-04-16 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
EP4175630A1 (fr) 2020-07-01 2023-05-10 Ecstasy LLC Amines polycycliques pour la modulation du récepteur opioïde

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1936452C3 (de) * 1969-07-17 1975-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenylpiperidlnen
US4016280A (en) 1969-07-17 1977-04-05 Byk Gulden Lomberg Chemische Fabrik Gmbh 4,4-Diarylpiperidine compositions and use
DE2139085C3 (de) * 1971-08-04 1979-01-18 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
DE2166997C3 (de) 1971-08-04 1980-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
DE2139084C3 (de) 1971-08-04 1979-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
ES2066721B1 (es) * 1993-05-18 1996-02-16 Ferrer Int Nuevos compuestos derivados de la piridina 1,4-disustituida.
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
EP0819001A1 (fr) * 1995-04-05 1998-01-21 Byk Gulden Lomberg Chemische Fabrik GmbH Utilisation de composes de piperidine ou de pyrrolidine substitues pour le traitement de maladies modulees par un recepteur sigma
WO1997042956A1 (fr) 1996-05-16 1997-11-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines et leurs emplois
WO1997045423A1 (fr) 1996-05-31 1997-12-04 Trophix Neuroscience Inc. Produit pharmaceutique pour le traitement de troubles neurologiques et neuropsychiatriques

Also Published As

Publication number Publication date
NO20011183D0 (no) 2001-03-08
AR022376A1 (es) 2002-09-04
BG105411A (bg) 2001-12-29
ATE312819T1 (de) 2005-12-15
AU5383799A (en) 2000-03-27
TNSN99169A1 (fr) 2005-11-10
NZ509841A (en) 2003-08-29
PA8481301A1 (es) 2000-09-29
EP1112255A1 (fr) 2001-07-04
US6720336B2 (en) 2004-04-13
CN1316993A (zh) 2001-10-10
PL346648A1 (en) 2002-02-25
GT199900146A (es) 2001-02-24
DE69928945T2 (de) 2006-07-27
PE20001053A1 (es) 2000-10-14
HUP0103542A3 (en) 2002-11-28
EE200100145A (et) 2002-06-17
CA2343236C (fr) 2006-01-03
SK3032001A3 (en) 2002-04-04
DE69928945D1 (de) 2006-01-19
KR20010075024A (ko) 2001-08-09
AP2001002088A0 (en) 2001-03-31
WO2000014066A1 (fr) 2000-03-16
YU11501A (sh) 2003-10-31
EA200100203A1 (ru) 2001-08-27
HN1999000149A (es) 2000-01-12
ZA200101744B (en) 2002-06-03
HUP0103542A2 (hu) 2002-01-28
OA11648A (en) 2004-12-08
CZ2001850A3 (cs) 2001-12-12
SV1999000147A (es) 2000-09-06
HRP20010167A2 (en) 2002-02-28
JP2002524445A (ja) 2002-08-06
US20040138220A1 (en) 2004-07-15
TR200100694T2 (tr) 2001-10-22
GEP20033025B (en) 2003-07-25
IL141506A0 (en) 2002-03-10
ID29129A (id) 2001-08-02
US20020013321A1 (en) 2002-01-31
NO20011183L (no) 2001-05-04
MA26686A1 (fr) 2004-12-20
EP1112255B1 (fr) 2005-12-14
IS5860A (is) 2001-02-23
HK1040396A1 (zh) 2002-06-07
BR9913512A (pt) 2001-06-05
AU749096B2 (en) 2002-06-20
CO5170416A1 (es) 2002-06-27
ES2252960T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
CA2343236A1 (fr) Derives de 4,4-biarylpiperidine
CA2258548A1 (fr) Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
CA2401033A1 (fr) Derives de 2-oxo-1-pyrrolidine, procedes de preparation et utilisations desdits derives
CA2274464A1 (fr) Cetobenzamides s'utilisant comme inhibiteurs de la calpaine
CA2475113A1 (fr) Derives isothiazole utiles en tant qu'agents anticancereux
CA2293382A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents anti-inflammatoires
CA2414095A1 (fr) Nouveaux composes
HK1048990A1 (en) Novel compounds.
CA2352505A1 (fr) Derives d'epothilone et leur utilisation comme agents antitumoraux
BG103417A (en) Condensed pyrimidine bicyclic derivatives
CA2316921A1 (fr) Composes azapolycycliques fusionnes avec un aryle
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
CA2278201A1 (fr) Nouvelles modifications du 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene et procedes de preparation connexes
CA2273479A1 (fr) Derives de 6-phenylpyridyl-2-amine utiles comme inhibiteur nos
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
CA2244785A1 (fr) Pentafluorobenzenesulfonamides et analogues
CA2243504A1 (fr) Nouveaux derives de 19-nor-pregnene
CA2338600A1 (fr) Nouveaux composes de thiazolopyrimidine
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
CA2152771A1 (fr) Derives 7-o-ether de taxane
WO1999012933A3 (fr) Derives de pyrrolopyrrolone en tant qu'inhibiteurs de neutrophile elastase
CA2219359A1 (fr) Derives hydantoine utilises comme produits intermediaires pour principes actifs pharmaceutiques
PT1427417E (pt) Derivados de 6, 7-di-hidroxitetra-hidroisoquinolina substituída em 3 para utilização como agentes antibacterianos
CA2299036A1 (fr) Derives de 4-phenyl-4-heteroarylpiperidine
CA2399377A1 (fr) Nouveaux modulateurs (paarm) allosteriques positifs de recepteurs ampa, leur methode de production et leur utilisation comme medicaments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed